Agentix Corp.

Agentix Corp. is a clinical development stage corporation focused on pharmaceutical treatments in the metabolic disease space. The company was incorporated in Nevada on April 18, 2013, and its fiscal year ends on March 31. Effective June 17, 2019, the company changed its name from FairWind Energy, Inc. to Agentix Corp. On May 28, 2020, Agentix Corp. entered into a Share Exchange Agreement with GSL Healthcare, Inc., a Nevada corporation, and its two common stockholders. The transaction closed on June 1, 2020. Under the agreement, Agentix Corp. issued and sold 27,932,271 shares of its common stock in exchange for all outstanding shares of GSL Healthcare common stock. As a result, the two former GSL Healthcare shareholders now own approximately 88.0% of Agentix Corp.'s issued common stock, and GSL Healthcare is a wholly-owned subsidiary. Following this agreement, Agentix Corp. shifted its business focus to developing and commercializing new therapeutics for metabolic diseases. The company's primary objective is to develop two key assets specifically designed not to cross the blood-brain barrier, meaning they are "peripherally-restricted." In September 2022, Agentix Corp. established a subsidiary, Agentix Australia Pty Ltd, in Australia. This subsidiary conducts development activities for the company's two key assets and participates in a tax rebate program that reimburses 43.5% of expenses for biotechnology and/or pharmaceutical development activities conducted in Australia. Agentix Corp. has not yet generated or realized meaningful revenues from its business.